T. Rowe Price Associates
WGS icon

T. Rowe Price Associates’s GeneDx Holdings WGS Stock Holding History

T. Rowe Price Associates’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48M Sell
23,026
-390,965
-94% -$35.7M ﹤0.01% 1964
2025
Q4 		$53.8M Buy
413,991
+82,583
+25% +$11.3M 0.01% 799
2025
Q3 		$35.7M Buy
331,408
+316,353
+2,101% +$34.5M ﹤0.01% 894
2025
Q2 		$1.39M Buy
15,055
+4,040
+37% +$317K ﹤0.01% 1822
2025
Q1 		$977K Sell
11,015
-55,953
-84% -$4.85M ﹤0.01% 1968
2024
Q4 		$5.15M Buy
66,968
+3,390
+5% +$237K ﹤0.01% 1286
2024
Q3 		$2.7M Buy
63,578
+16,406
+35% +$554K ﹤0.01% 1502
2024
Q2 		$1.23M Buy
47,172
+3,889
+9% +$73.7K ﹤0.01% 1802
2024
Q1 		$396K Sell
43,283
-16
-0% -$96 ﹤0.01% 2302
2023
Q4 		$120K Hold
43,299
– – ﹤0.01% 2689
2023
Q3 		$158K Sell
43,299
-453
-1% -$2.48K ﹤0.01% 2565
2023
Q2 		$261K Sell
43,752
-4,755
-10% -$37.6K ﹤0.01% 2428
2023
Q1 		$585K Sell
48,507
-1,462
-3% -$19.5K ﹤0.01% 2035
2022
Q4 		$435K Sell
49,969
-2,404
-5% -$53K ﹤0.01% 2196
2022
Q3 		$1.52M Buy
52,373
+1,058
+2% +$48.4K ﹤0.01% 1557
2022
Q2 		$2.13M Sell
51,315
-3,785
-7% -$257K ﹤0.01% 1594
2022
Q1 		$5.58M Sell
55,100
-33,765
-38% -$3.75M ﹤0.01% 1448
2021
Q4 		$13.1M Buy
88,865
+2,428
+3% +$542K ﹤0.01% 1366
2021
Q3 		$21.6M Buy
+86,437
New +$29.7M ﹤0.01% 1273

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's WGS Position: Q1 2026 in Review

T. Rowe Price Associates reduced its GeneDx Holdings (WGS) stake by 94% in Q1 2026, selling an estimated $35.7M and leaving 23,026 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

T. Rowe Price Associates first reported a position in WGS in Q3 2021 and has held it in 19 quarters since. The position peaked at $53.8M in Q4 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • T. Rowe Price Associates held 23,026 shares of GeneDx Holdings worth $1.48M as of Q1 2026.
  • T. Rowe Price Associates sold 390,965 GeneDx Holdings shares in Q1 2026, an estimated $35.7M.
  • GeneDx Holdings made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1964 holding.
  • T. Rowe Price Associates first reported a position in GeneDx Holdings in Q3 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's GeneDx Holdings position peaked at $53.8M in Q4 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.